The collaboration combines Intellia’s CRISPR-based gene editing platform incl. DNA writing technology with ReCode’s SORT LNP delivery platform to correct CF disease-causing gene mutations
The companies will initially focus on developing therapies for CF patients with limited or no treatment options. As per the agreement, Intellia will design the editing strategy & research-grade components for the investigational therapies & ReCode will lead the subsequent pre/clinical development & commercialization of certain programs globally
Intellia will be eligible to receive a pre-specified development & commercial milestone payment, plus royalties & is also eligible to exercise an option to lead commercialization across the US for certain programs
Ref: Intellia Therapeutics | Image: Intellia Therapeutics
Related News:- Vertex’s Kaftrio+Ivacafor Receives EC’s Approval for the Treatment of Children aged 2 to 5yrs. with Cystic Fibrosis (CF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
